AR099766A1 - Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos - Google Patents

Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos

Info

Publication number
AR099766A1
AR099766A1 ARP150100787A ARP150100787A AR099766A1 AR 099766 A1 AR099766 A1 AR 099766A1 AR P150100787 A ARP150100787 A AR P150100787A AR P150100787 A ARP150100787 A AR P150100787A AR 099766 A1 AR099766 A1 AR 099766A1
Authority
AR
Argentina
Prior art keywords
inhibitors
adapter
compositions
methods
kinase associated
Prior art date
Application number
ARP150100787A
Other languages
English (en)
Inventor
Bi Yingzhi
Kumi Godwin
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of AR099766A1 publication Critical patent/AR099766A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es el 3-metiloxetan-3-il-4-(3-(2-metoxipiridin-3-il)pirazolo[1,5-a]pirimidin-5-il)piperazin-1-carboxilato de fórmula (1) o una sal farmacéuticamente aceptable del mismo.
ARP150100787A 2014-03-17 2015-03-16 Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos AR099766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461953976P 2014-03-17 2014-03-17

Publications (1)

Publication Number Publication Date
AR099766A1 true AR099766A1 (es) 2016-08-17

Family

ID=52727478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100787A AR099766A1 (es) 2014-03-17 2015-03-16 Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos

Country Status (15)

Country Link
US (1) US9682982B2 (es)
EP (2) EP3719021B1 (es)
JP (1) JP6553081B2 (es)
CN (1) CN106103447B (es)
AR (1) AR099766A1 (es)
AU (1) AU2015231672B2 (es)
CA (1) CA2941870C (es)
DK (2) DK3719021T3 (es)
ES (2) ES2821441T3 (es)
HK (1) HK1226065A1 (es)
HU (1) HUE050975T2 (es)
PL (2) PL3719021T3 (es)
PT (2) PT3719021T (es)
TW (1) TW201620911A (es)
WO (1) WO2015142714A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630721A (en) * 2012-03-09 2016-12-23 Lexicon Pharmaceuticals Inc Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
CN109369576B (zh) * 2018-09-19 2020-11-27 上海凌凯医药科技有限公司 一种合成3-甲基氧杂环丁烷-3-(4-硝基苯基)碳酸酯的方法
JP2023522688A (ja) 2020-04-21 2023-05-31 レクシコン ファーマシューティカルズ インコーポレイテッド ウイルス感染症の治療に使用されるａａｋ１阻害剤
EP4138844A1 (en) * 2020-04-21 2023-03-01 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
WO2023196584A2 (en) * 2022-04-08 2023-10-12 New York University Endocytosis inhibitors and their use for pain treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011030139A1 (en) * 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
EP2523552B1 (en) * 2010-01-14 2015-05-13 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
ES2676826T3 (es) * 2012-03-09 2018-07-25 Lexicon Pharmaceuticals, Inc. Compuestos basados en imidazo[1,2-b]piridazina, composiciones que los comprenden y usos de los mismos
EP3235499A3 (en) * 2012-03-09 2018-01-17 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
NZ630721A (en) * 2012-03-09 2016-12-23 Lexicon Pharmaceuticals Inc Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

Also Published As

Publication number Publication date
AU2015231672A1 (en) 2016-09-15
CA2941870C (en) 2022-07-19
PT3719021T (pt) 2022-04-08
US9682982B2 (en) 2017-06-20
EP3119783A1 (en) 2017-01-25
US20160039824A1 (en) 2016-02-11
PT3119783T (pt) 2020-09-24
CN106103447B (zh) 2019-07-16
PL3719021T3 (pl) 2022-06-20
AU2015231672B2 (en) 2019-06-20
CN106103447A (zh) 2016-11-09
PL3119783T3 (pl) 2021-01-11
DK3119783T3 (da) 2020-09-28
TW201620911A (zh) 2016-06-16
EP3119783B1 (en) 2020-06-24
HUE050975T2 (hu) 2021-01-28
WO2015142714A1 (en) 2015-09-24
HK1226065A1 (zh) 2017-09-22
EP3719021A1 (en) 2020-10-07
ES2821441T3 (es) 2021-04-26
EP3719021B1 (en) 2022-03-09
CA2941870A1 (en) 2015-09-24
DK3719021T3 (da) 2022-06-13
JP6553081B2 (ja) 2019-07-31
ES2911388T3 (es) 2022-05-19
JP2017507980A (ja) 2017-03-23

Similar Documents

Publication Publication Date Title
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
DOP2023000077A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2016000241A1 (es) Formulación de inhibidores de la syk.
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
PH12016502252A1 (en) Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
GT201400196A (es) Compuestos de heterociclilo
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
AR103680A1 (es) Inhibidores selectivos de bace1
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
ECSP16074478A (es) Compuestos novedosos
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы

Legal Events

Date Code Title Description
FB Suspension of granting procedure